Get the Stockscreener App
0.5775
4.13%
-0.0249
Pre-market:
.57
-0.0075
-1.30%
Palisade Bio Inc stock is traded at $0.5775, with a volume of 10.84M.
It is down -4.13% in the last 24 hours and down -27.90% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$0.6024
Open:
$0.612
24h Volume:
10.84M
Relative Volume:
5.21
Market Cap:
$5.27M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.0413
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
+7.14%
1M Performance:
-27.90%
6M Performance:
-32.38%
1Y Performance:
-85.84%
1-Day Range:
$0.5465
$0.6591
1-Week Range:
$0.53
$0.6591
52-Week Range:
$0.53
$4.318
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
0.5775 | 5.61M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Palisade Bio Inc Stock (PALI) Latest News
tick level data insight on palisade bio inc. volatilityJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Can swing trading help recover from Palisade Bio Inc. lossesPortfolio Performance Summary & Safe Entry Trade Signal Reports - newser.com
Palisade Bio reports positive clinical data for PALI-2108 in UC - Investing.com Australia
Palisade Bio reports positive clinical data for PALI-2108 in UC By Investing.com - Investing.com South Africa
Palisade Bio reports positive PALI-2108 phase 1b clinical data - MarketScreener
Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data - GlobeNewswire
100% Clinical Response: Palisade Bio's Novel UC Drug Shows Promise in Phase 1b with Zero Serious Side Effects - Stock Titan
Real time alert setup for Palisade Bio Inc. performanceTrade Ideas & Low Risk Investment Opportunities - newser.com
Using economic indicators to assess Palisade Bio Inc. potentialQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Can Palisade Bio Inc. recover in the next quarter2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Market Trends: Is Palisade Bio Inc. benefiting from interest rate changesEarnings Risk Summary & Target Return Focused Stock Picks - خودرو بانک
Aug PreEarnings: Will Palisade Bio Inc outperform its industry peers2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - خودرو بانک
Best data tools to analyze Palisade Bio Inc. stockTrade Entry Report & Smart Money Movement Tracker - newser.com
Quarterly Trades: Does Palisade Bio Inc have declining or rising EPSPortfolio Performance Summary & Growth Focused Stock Pick Reports - خودرو بانک
Is Palisade Bio Inc. stock bottoming outIndex Update & Long-Term Growth Plans - newser.com
Ideas Watch: Will Palisade Bio Inc stock recover after earnings2025 Institutional Moves & AI Optimized Trading Strategy Guides - خودرو بانک
What machine learning models say about Palisade Bio Inc.Weekly Risk Summary & Capital Efficient Trading Techniques - newser.com
Key resistance and support levels for Palisade Bio Inc.Market Sentiment Report & Weekly Sector Rotation Insights - newser.com
Aug Spikes: Can Silicom Ltd maintain its current growth rateWeekly Profit Summary & Expert-Curated Trade Recommendations - خودرو بانک
Tick level data insight on Palisade Bio Inc. volatility2025 Investor Takeaways & Verified Trade Idea Suggestions - newser.com
Can trapped investors hope for a rebound in Palisade Bio Inc.Portfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Sentiment analysis tools applied to Palisade Bio Inc.Quarterly Market Summary & Expert Approved Momentum Ideas - Newser
Relative strength of Palisade Bio Inc. in sector analysis2025 Bull vs Bear & Daily Entry Point Trade Alerts - Newser
Advanced analytics toolkit walkthrough for Palisade Bio Inc.Market Volume Report & Free High Accuracy Swing Entry Alerts - Newser
Will Palisade Bio Inc. continue its uptrendQuarterly Portfolio Summary & Low Volatility Stock Recommendations - Newser
Is now a turning point for Palisade Bio Inc.Quarterly Market Review & Capital Efficiency Focused Strategies - Newser
Quantitative breakdown of Palisade Bio Inc. recent moveInflation Watch & Reliable Intraday Trade Plans - Newser
Exit strategy if you’re trapped in Palisade Bio Inc.2025 Analyst Calls & Technical Pattern Alert System - Newser
Using data models to predict Palisade Bio Inc. stock movement2025 Short Interest & Fast Gaining Stock Reports - Newser
When is the best time to exit Palisade Bio Inc.Dividend Hike & Daily Entry Point Trade Alerts - Newser
Price momentum metrics for Palisade Bio Inc. explainedJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - Newser
Is Palisade Bio Inc. meeting your algorithmic filter criteriaWall Street Watch & Long-Term Capital Growth Strategies - Newser
Risk adjusted return profile for Palisade Bio Inc. analyzedQuarterly Portfolio Summary & Daily Oversold Stock Bounce Ideas - Newser
What earnings revisions data tells us about Palisade Bio Inc.2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - Newser
Tools to assess Palisade Bio Inc.’s risk profileLayoff News & Reliable Breakout Forecasts - Newser
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):